Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F‐18]fluorodeoxyglucose positron emission tomography

Lowe, Val J.; Dunphy, Frank; Varvares, Mark A.; Kim, H.; Wittry, Mark D.; Dunphy, Cherie H.; Dunleavy, Teresa L.; McDonough, Erin; Minster, Jeffrey R.; Fletcher, James; Boyd, James H.

doi:10.1002/(sici)1097-0347(199712)19:8<666::aid-hed4>3.3.co;2-c

Cited by 16 publications

(23 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Changes in FDG-PET imaging following neoadjuvant chemotherapy are predictive of histologic response in patients with breast carcinoma [10,11], head and neck carcinoma [12], lymphoma [13,14], and gastrointestinal stromal tumors [15].…”

mentioning

confidence: 99%

Evaluation of chemotherapy response in osteosarcoma with FDG-PET

et al. 2009

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Evaluation of chemotherapy response in osteosarcoma with FDG-PET

et al. 2009

View full text Add to dashboard Cite

show abstract

“…They found in eight out of nine patients (89%) with persistent or recurrent disease elevated FDG uptake after RT. Lowe et al (1997) reported a mean reduction of 82% in FDG uptake in those who achieved a complete remission compared to a decrease of 34% uptake in those who demonstrated recurrent disease.…”

Section: Head and Neck Cancermentioning

confidence: 98%

Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology

Stokkel

Draisma

Pauwels

2001

Journal of Cancer Research and Clinical Oncology

View full text Add to dashboard Cite

Positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) is considered to be a very useful adjunct to anatomic imaging techniques and is now primarily used for oncological indications. These indications include diagnosis, staging, and therapy monitoring. In this review, we discuss the articles in which FDG-PET is clinically used for monitoring therapy in lung and colorectal tumours, head and neck cancer, sarcoma, and hepatocellular carcinoma. It is found that the amount of FDG uptake strongly correlates with response to therapy: a decrease in FDG uptake after therapy indicates a positive response to therapy. However, this conclusion is based on small numbers of patients, whereas the exact response mechanism is still unknown. Moreover, in these case series, the interval between tumour therapy and FDG-PET, as well as the method of quantification, SUV or tumour-to-non-tumour ratios, differ per study. Finally, dynamic imaging is a recommended technique by some authors, but it is not a standard technique in clinical practice to evaluate tumour therapy. Therefore, further study is required which has to deal with these major issues before it is possible to draw definite conclusions.

show abstract

“…Au moins 95 % des carcinomes des VADS de volume égal ou supérieur à 1 cm 3 fixent de manière significative le traceur [9], et cette fixation est fonction de la vascularisation et du degré du métabolisme du tissu étudié. Les micrométastases de dimension inférieure à 8 mm donnent de faux négatifs [20,25] …”

Section: La Tep Au Fdg En Orlunclassified

“…Enfin, en cas de prélèvements biopsiques, il est recommandé d'attendre quinze jours [25,41] avant de procéder à un examen TEP-FDG afin de ne pas assimiler les sites de prélèvements à des localisations malignes.…”

Section: Efficacité Réponse Au Traitementunclassified

“…À l'examen clinique elles apparaissent souvent oedémateu-ses, inflammatoires, associées à des zones ulcérées et granuleuses, sièges suspects d'une récidive tumorale. Les biopsies à l'aveugle sont fréquemment équivoques ; le résidu ou la récidive tumorale ne sont pas mis en évidence au sein d'un tissu en voie de reépithélisa-tion, mal vascularisé et cicatriciel [25,26,32]. De plus, les chirurgiens sont peu enthousiastes pour pratiquer des biopsies multiples et profondes chez ce type de patient de peur d'initier ou d'aggraver une radionécrose.…”

Section: Maladies Résiduelles Et Récidivesunclassified

See 1 more Smart Citation

New imaging modalities and PET CT in head and neck cancers

Marcy

Fontana

2005

Oncologie

View full text Add to dashboard Cite

L'amélioration technologique et informatique explique l'évolution de l'imagerie médicale actuelle. Après un bref rappel historique, un état des lieux de l'imagerie actuelle concernant l'écho-graphie cervicale, la TDM et l'IRM cervico-faciale en oncologie, sera exposé. Les développements attendus seront explicités en première partie de chapitre. La place exacte de la TEP qui donne des images fonctionnelles « métaboliques », et des autres techniques d'imagerie, sera discutée en seconde partie d'exposé, en insistant sur l'avenir de la fusion des images entre l'imagerie « anatomique » et l'imagerie « fonctionnelle » en oncologie ORL.Mots clés : Imagerie médicale -Imagerie en oncologie -TEP scanner -Cancer cervico-facial New imaging modalities and PET CT in head and neck cancersAbstract: The advancement of imaging modalities and the availability of high-performance computing are being developed at an impressive rate and provide an entire new dimension for medical imaging of patients with head and neck cancer. Indeed, across a broad front of imaging technologies, rapid advances are being realized. In the first part of the topic, the authors will discuss the recent developments concerning ultrasonography of the neck, head and neck CT and MRI imaging modalities in oncology. Functional imaging modalities like positron emission tomography (PET), may significantly influence the staging and treatment approaches used for head and neck cancer patients. Indications for PET CT, image fusion system for MRI, CT, and PET images will be discussed in the second part of the topic.

show abstract

Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F‐18]fluorodeoxyglucose positron emission tomography

Cited by 16 publications

References 4 publications

Evaluation of chemotherapy response in osteosarcoma with FDG-PET

Evaluation of chemotherapy response in osteosarcoma with FDG-PET

Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology

New imaging modalities and PET CT in head and neck cancers

Contact Info

Product

Resources

About